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The advanced glycation end products (AGEs) are organic molecules formed in any living organisms with a great variety of
structural and functional properties. They are considered organic markers of the glycation process. Due to their great
heterogeneity, there is no specific test for their operational measurement. In this review, we have updated the most common
chromatographic, colorimetric, spectroscopic, mass spectrometric, and serological methods, typically used for the determination
of AGEs in biological samples. We have described their signaling and signal transduction mechanisms and cell epigenetic effects.
Although mass spectrometric analysis is not widespread in the detection of AGEs at the clinical level, this technique is highly
promising for the early diagnosis and therapeutics of diseases caused by AGEs. Protocols are available for high-resolution mass
spectrometry of glycated proteins although they are characterized by complex machine management. Simpler procedures are
available although much less precise than mass spectrometry. Among them, immunochemical tests are very common since they
are able to detect AGEs in a simple and immediate way. In these years, new methodologies have been developed using an
in vivo novel and noninvasive spectroscopic methods. These methods are based on the measurement of autofluorescence of
AGEs. Another method consists of detecting AGEs in the human skin to detect chronic exposure, without the inconvenience of
invasive methods. The aim of this review is to compare the different approaches of measuring AGEs at a clinical perspective due
to their strict association with oxidative stress and inflammation.
1. Introduction
AGEs are heterogeneous molecules derived from the nonen-
zymatic products of reactions of glucose or other saccharide
derivatives with proteins or lipids [1]. Various environmen-
tal factors, including cigarette smoke, high levels of refined
and simple carbohydrate diets, hypercaloric diets, high
temperature-cooked foods, and sedentary lifestyle, induce
AGE production and consequently damage cell lipids and
proteins [1, 2]. In this context, oxidative stress disturbs cell
signal transduction, especially insulin-mediated metabolic
responses, and this in turn can bring about a remarkable
alteration of their normal function [3]. AGEs, through the
promotion of oxidative stress, lead the activation of several
stress-induced transcription factors, with the production of
proinflammatory and inflammatory mediators such as cyto-
kines and acute-phase proteins [2].
More than 20 different AGEs have been identified in
human blood and tissues and in foods. In summary, AGEs
can be divided into fluorescent and nonfluorescent AGEs.
The most important ones include carboxymethyl-lysine
(CML), carboxyethyl-lysine (CEL), pyrraline (nonfluorescent
AGEs), pentosidine, and methylglyoxal-lysine dimer (MOLD)
(fluorescent AGEs) [4, 5]. Although they own diverse chemical
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structures, their common characteristic is the presence of
lysine residue in their molecule. When there is an overpro-
duction of AGEs, an imbalance between AGEs (endogenous
production and exogenous intake) and effective mechanism
of the AGE detoxification system as their excretion from
kidneys occurs [6]. AGE accumulation causes cumulative
metabolic burden (both hyperglycemia and hyperlipidemia),
inflammation, and oxidative stress [7].
In this context, oxidative stress, inflammatory response,
and endothelial dysfunction are linked by binding to recep-
tors for AGE (RAGEs) [8].
RAGEs are multiligand receptors belonging to an immu-
noglobulin superfamily which is expressed in a wide range of
tissue, including the vasculature, lung, heart, endothelium,
and neural tissue. Furthermore, they are expressed on a wide
range of cells, including smooth muscle cells, monocytes,
macrophages, endothelial cells, astrocytes, and microglia [9].
Under healthy conditions, RAGEs are expressed at basal levels;
however, levels elevated are found under pathological condi-
tions such as diabetes mellitus (DM), cardiovascular disease,
Alzheimer’s disease, cancer, and natural aging [10, 11].
The activation of RAGE induces an inflammatory cas-
cade that starts with activation of a transcription factor
nuclear factor-kappa B (NF-κB) that promotes the expres-
sion of proinflammatory cytokines, growth factor, and adhe-
sive molecules [12, 13]. Specifically, the engagement of RAGE
increases oxidative stress by activating NADPH oxidase that
also increases in NF-κB stimulation [14]. Another group of
cell surface receptor for AGEs with opposite function to
RAGE, known as AGE-R1, AGE-R2, or AGE-R3, is instead
involved in the regulation of endocytosis and clearance of
AGEs [15, 16].
For example, AGE-R1 has been shown to be involved in
pathways that decrease intracellular oxidative stress [16].
Many chronic and age-related diseases reduce the expression
of AGE-R1 [16]. There is also a circulating pool of RAGE,
collectively known as soluble RAGE (sRAGE), whose role
remains controversial, and a minor alternatively spliced iso-
form of RAGE known as endogenous secretory RAGE
(esRAGE) [17]. The functions of these receptors will be
explained in detail and subsequently.
Due to the broad range of polarities and different struc-
tures of AGEs, there is no universally accepted method to
measure them for clinical purposes. The lack of standardized
methods and reference materials increases the risk to commit
measurement errors and reduces the degree of accuracy and
reproducibility of these methods [18]. In addition, most of
the research works have been limited to monitor AGE levels
in pathophysiologic conditions.
In recent years, extensive research has revealed impor-
tant roles of AGEs in the progression mechanisms driving
to diabetes, cardiovascular disease (CVD), hypertension,
chronic inflammation, and other chronic diseases [19, 20].
Various examples of measurements of AGE’s level using
the qualitative and quantitative approaches have been shown
with different fluid samples: high-performance liquid chro-
matography (HPLC), mass spectrometry (MS/MS), and gas
chromatography (GC) [21]. Besides, AGEs or CML and
MG derivatives are typically quantified by enzyme-linked
immunosorbent assay (ELISA) [22–24]. For more than a
decade, in vivo spectroscopy methodologies allow the mea-
surement of autofluorescence of AGEs through detection in
the human skin without the use of invasive methods [25].
Blood measurements of AGEs are indicative of their short-
term presence and do not provide the state of their accumu-
lation in tissues. Monitoring individual AGE status in healthy
as well as diseased subjects may be a potent tool to slow down
the onset and development of the chronic disease. This will
also improve our understanding of disease pathogenesis
and permit the development of new therapeutic strategies.
However, methods based on the detection of autofluores-
cence of AGEs are limited as they exclusively measure the
total fluorescent glycation. New promising methodologies
for high-throughput generation of monoclonal antibodies
mapped with epitopes against AGE have been applied and
validated [26, 27]. Signs of progress have been obtained in
identifying epitopes, reaching a high level of sensitivity and
a simple analytical procedure [26, 27]. However, improve-
ments in cultivation techniques and in the construction of
specific monoclonal epitopes represent important goals to
be achieved. Currently, no gold standard method is available
for the detection and quantification of AGEs.
The aim of this review is to describe different approaches
for AGE’s measurements and provide scientific evidence of
their association with oxidative stress, inflammation, and
epigenetic effects.
2. AGE’s Biochemistry
Numerous studies showed that the AGEs and the advanced
lipoxidation end products (ALEs) are involved in the devel-
opment and progression of chronic degenerative diseases,
including diabetes [28–30], cardiovascular diseases [29, 31,
32], neurological disorder [33, 34], some types of cancer
[35, 36], and all those pathologies in which the mechanisms
of oxidative stress are involved, as well as the senescence pro-
cesses [33].
The AGEs are heterogeneous compounds derived from
nonenzymatic products of glucose reactions or other saccha-
ride derivatives with proteins or lipids and can be formed
with either exogenous or endogenous mechanisms. The
ALE includes a variety of covalent molecules which are gen-
erated by the nonenzymatic reaction of reactive carbonyl
species (RCS), produced by lipid peroxidation and lipid
metabolism [30].
AGEs and ALEs have a similar structure because they
derive from common precursors, such as CML which is syn-
thesized by glyoxal, a product of degradation of lipid and
sugar. Furthermore, they are produced by nonenzymatic
mechanisms and oxidative stress that are involved in the
mechanism of their formation [37].
The Maillard reaction (MR) is characterized by nonen-
zymatic reactions of reducing sugars with amines. The sta-
ble products of this reaction are referred to as AGEs and
were initially identified in cooked foods [38]. The early
stage of MR leads the formation of nonstable products,
known as Schiff bases which are generated as a result of
condensation reactions between the electrophilic carbonyl
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group of a reducing sugar with free amino groups, essentially
lysine or arginine [39]. The consequent rearrangement leads
to the formation of a stable ketoamine, called Amadori prod-
uct. Both compounds are reversible reaction products, and
they may react irreversibly with peptides or proteins to form
protein cross-links. Besides, these compounds may partici-
pate in oxidation, dehydration, or polymerization reactions
to give to numerous other AGEs [39, 40].
In this context, reactive oxygen species (ROS) play a key
role to catalyse the formation of advanced glycoxidation end
products [41]. AGEs are a heterogeneous class of compounds
which own diverse chemical structures. Initial investigations
were concerned with the reaction between sugars and hae-
moglobin A1c (HbA1c), known as glycated haemoglobin in
diabetes. Mechanisms of its formation include the addition
of glucose molecules to amino groups located on haemoglo-
bin β-chains with the formation of a Schiff base that is an
unstable structure driving an Amadori rearrangement. The
final product, 1-deoxy-1-fructosyl residue, owns a carbohy-
drate fragment attached to the HbA1c. The structure of a
fructosyl-lysine molecule is shown in Figure 1. In these years,
numerous other AGEs have been identified in vivo and
in vitro. They are classified in different groups based on their
chemical structures and ability to emit fluorescence.
These are as follows:
(1) Fluorescent and cross-linked (fluorescent/cross-
linked)
(2) Nonfluorescent and non-cross-linked (nonfluores-
cent/non-cross-linked)
(3) Nonfluorescent protein cross-linked
(4) Fluorescent non-cross-linked
The first isolated and characterized fluorescent cross-
linked AGEs are pentosidine (Figure 2). They are obtained
from collagen and composed of an arginine and lysine resi-
dues cross-linked to a ribose but also from hexoses and ascor-
bic acid [42]. The level of pentosidine can be regarded as a
major glycoxidative end product [43], and therefore, it is
widely used as a measure of total AGE accumulation in
plasma or other tissues [44]. Pentosidine is not the only nat-
ural fluorescent cross-linked AGE; other fluorescent cross-
linked AGEs are pentodilysine, crossline, AGE-XI, vesperly-
sine A, and vesperlysine C. Several other cross-linkers but
nonfluorescent compounds have been identified (Figure 3).
The main AGE structures belonging to this group are imida-
zolium dilysine cross-links also known as glyoxal-lysine dimer
(GOLD) or methylglyoxal-lysine dimer (MOLD) cross-links
[45] which derive from the reaction between two lysine side-
chains and two molecules of glyoxal (GO) and methylglyoxal
(MG), respectively.
Other related cross-links of arginine, known as imida-
zolium cross-link derived from glyoxal and lysine-arginine
(GODIC) and imidazolium cross-link derived from methyl-
glyoxal and lysine-lysine (MODIC), have been isolated
from bovine serum albumin (BSA) [46, 47]. These com-
pounds belonging to this group are highly reactive mole-
cules and therefore lead to the cross-linking of proteins.
Important nonfluorescent and non-cross-linked AGEs
include CML, carboxyethyl-lysine (CEL), pyrraline, and
imidazolones [48] (Figure 4), which have been extensively
studied and implicated in diabetes, inflammation, and other
diseases [49–51].
These compounds are of importance in vivo and can be
used to monitor the level of AGE accumulation during path-
ological conditions such as diabetes. CML represents the
most prevalent AGE in vivo [52, 53], and it is frequently used
as the AGE marker [54]. It can be formed through various
pathways, including condensation of glucose with lysine of
the amino group and successively rearrangement of the
Amadori product, which undergoes oxidation and forms
CML. Another pathway consists of the reaction directly
between glyoxal (GO) and lysine of the amino group [55].
Another important compound is pyrraline obtained by
reaction between glucose and lysine residues of proteins. This
compound owns importance in vivo and is regarded as an
AGE accumulation marker throughout life and in diabetes
[56]. In addition to cross-linked AGEs, a range of fluorescent
non-cross-linked AGEs are detected in the blood of diabetic
patients (Figure 5). They are structurally like fluorescent
cross-linked AGEs, except that one of the bonds links the
heterocyclic part with the amino acid and is replaced by the
N-H bond.
They also involve promoting a variety of undesired
changes at cellular and tissue levels through the mechanism
of biological receptor [57].
Argpyrimidine is a typical example of AGE structure
belonging to this family of fluorescent non-cross-linked
AGEs. It is formed from arginine and methylglyoxal through
the Maillard reaction, and it has been studied for its food
chemistry purposes and its potential involvement in elevated
oxidative stress content in several tissues [58, 59]. AGEs may
derive from an exogenous source, through food consumption
and tobacco smoke (Figure 6). During the normal metabolic
processes of a healthy organism, AGEs and their precursors
are also formed at lower rates, while they are increased in
diabetes [54], atherosclerosis [60], and other chronic pathol-
ogies. Besides, various environmental factors, such as West-
ern diet, cigarette smoke, or inflammation, induce a high
AGE production. For example, cigarette smoke contains
high concentrations of GO and MG and provokes the accu-
mulation of other AGEs in plasma of smokers [61].
Glyceraldehyde, in the form of glyceraldehyde 3-phos-










Figure 1: Examples of fructosyl-lysine.
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glycolysis, is involved in the formation of GLAP com-
pound (glyceraldehyde-derived pyridinium), a compound
glyceraldehyde-derived advanced glycation end product
(AGE). Specifically, when glyoxidation occurs, new com-
pounds are formed, like methylglyoxal (MG) and glyoxal.
These in turn can also react with proteins. In this case, MG
reacts mainly with arginine while glyoxal reacts with lysine
residual. Advanced glycation derived from glyceraldehyde
(GLAP) is elevated in oxidation stress, inflammatory, and/or
diabetic conditions, endothelial dysfunction, and vascular
inflammation [62–64]. High levels of GLAP have been
detected in Alzheimer’s disease [65]. GLAP, such as pentosi-
dine and other AGE compounds, is a biomarker involved in
metabolic diseases such as diabetic and vascular complica-
tions [66, 67]. A recent prospective study in European popu-
lations has shown that GLAP may promote colorectal
cancers (CRC) through proinflammatory and prooxidative
ways [68]. However, although circulating GLAP were not
associated with the overall risk of CRC, a positive association
was found. Measurement errors of interpretation may be
underestimated. The detection of GLAP was conducted
through ELISA. Due to the underestimation of the circulat-
ing GLAP detection, further research is needed to clarify
the role of toxic carbohydrate metabolism products in the
pathogenesis of CRC development. Once again, more precise
and large-scale techniques are needed.
Moreover, variations of circulating AGEs may also be
influenced by the genetic ability to detoxification mecha-
nisms against the accumulation of AGEs [69]; therefore, the
content of AGEs in the organism depends not only by the
rate of their formation but also by the ability to being
removed through intrinsic detoxifying pathways. Several
possible mechanisms of detoxification against AGEs include
reduced glutathione (GSH) which catalyzes the conversion
of GO and methylglyoxal (MG) to the less toxic D-lactate
[70]. Other enzymatic systems include fructosamine kinases
[71], which act on phosphorylating and destabilizing Ama-
dori products leading to their spontaneous breakdown.
3. RAGE: Receptor for AGEs
The RAGE is a transmembrane protein belonging to the
immunoglobulin superfamily of cell surface receptors, encoded
by a gene on chromosome 6 near the major histocompat-
ibility complex III [72]. The gene consists of 11 exons, and
typical variations of this gene have been described [73].
RAGE consists of an extracellular region characterized by
the immunoglobulin domains of types V1, C1, and C2,
transmembrane-spanning domain, and short cytosolic tail
[9, 11]. The extracellular part of a RAGE molecule is com-
posed of a variable (V-type) domain, which is followed by
two constant (C-type) domains and represents the main
binding sites for various ligands, while the cytosolic tail
of RAGE is essential for signaling [9]. Domains of type
V1 and C1 of RAGE bind a large variety of molecules
(Figure 7), not only AGEs (endogenous or food-derived)
but also advanced oxidation protein products (AOPPs),
involved in oxidative stress [35], β-amyloid related to Alzhei-
mer’s disease [10, 74], calcium-binding S100 proteins linked
to several human cancers [75], and high-mobility group box-
1 (HMGB) expressed in cancer and inflammation [35, 76].
RAGE receptors have been identified in a series of organs
and tissues, but their highest concentration is in the lung,
















































Figure 2: Examples of fluorescent cross-linked AGEs.
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Figure 3: Examples of nonfluorescent cross-linked AGEs.
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on a wide range of cells including smooth muscle cells,
monocytes, macrophages, endothelial cells, astrocytes, and
microglia [8]. Under normal and healthy conditions, RAGE
is expressed at basal levels; however, levels elevated are found
under pathological conditions or chronic inflammation such
as diabetes mellitus (DM), cardiovascular disease, Alzheimer’s
disease, cancer, and natural aging [10, 11]. Furthermore, the
activation of RAGEs by AGEs or other ligands also trans-
duces multiple signals, such as the mitogen-activated protein
kinases (MAPKs), extracellular signal-regulated kinases 1
and 2 (ERK), p21ras, p38, and Janus kinase [77]. The binding
of ligands to RAGE activates various signaling pathways
which induce activation of the transcription factor nuclear
factor-kappa B (NF-κB) that increases the transcription
of many proinflammatory genes [10, 78], MAPK, trans-
ducers, and activators of the Janus kinase signal from tran-
scription (JAK-STAT), and phosphoinositol 3 kinase, and
consequently causes inflammatory, proliferative, angiogenic,
fibrotic, thrombogenic, and apoptotic reactions [79, 80]. The
binding AGE/RAGE increases the levels of ROS [81] through
activation of NADPH oxidase and mitochondrial pathways
[14]. Consequently, the activity of superoxide dismutase
(SOD), catalase and indirectly other endogenous antioxidant
defense is decreased, such as glutathione (GSH) and ascorbic
acid [82]. In fact, oxidative stress is highly related to glyca-
tion, since the depletion of GSH also reduces the activity
of Glyoxalase-I (Glo-1), thus increasing concentrations of
glyoxal and methylglyoxal (MG), formed nonenzymatically
as products, mainly in glycolysis, and leads to the formation
of AGEs [83]. It is interesting to note that AGE-R1 is down-
regulated by high levels of AGE [84]. Furthermore, other
studies have shown that AGEs increase the oxidation of
LDL and promote the development of atherosclerosis [85,
86]. Glycated LDLs are therefore more sensitive to oxidation
[86]; they are reduced with difficulty and promote the forma-
tion of antibodies that bind the AGEs located in the vessel
wall, which amplify the development of vascular inflamma-
tion and atherosclerosis [87]. Glo-1 overexpression has ben-
eficial vascular effects, reduces ROS, and protects against
atherogenic LDL formation [63, 88].
In patients with type 2 diabetes mellitus, circulating AGE
levels are positively correlated with RAGE mRNA expression
and oxidative markers, such as protein carbonyl, advanced
oxidation protein product (AOPP) generation, and lipid per-
oxidation [89]. In this context, RAGE is a strong upregula-
tion of NF-κB that leads to transcriptional activation of
different genes involved in inflammation including cell adhe-
sion molecules like E-selectin, ICAM-1, and VCAM, and
proinflammatory cytokines (IL-6, 8; TNF-α) [90, 91]. The
chronic inflammation signals, oxidative stress, and high
AGE content carry out the process of tumor initiation,
allowing the constitution of a microenvironment that initi-
ates a premalignant niche [92]. All these evidences always
happen through the link AGEs or ligands and RAGE. The
AGE-RAGE bond promotes the downstream enhancement
of the enzyme NADPH oxidase 2 (NOX2), consequently
ROS production, and NF-κB activation, which in turn pro-
motes further RAGE expression. Signaling axis AGE/RA-
GE/NOX2/NF-κB promotes inflammation and cancer [93].
All four components of this axis are expressed in high levels
in tumor tissues compared to the control [94]. Reduction or
inhibition of NF-κB activation is the goal of many therapeu-
tic interventions for diabetic, cardiac, pulmonary, and all
other pathologies dependent on AGE-RAGE interaction.
For example, blockade of the AGE/RAGE pathway is thus a
potential target to control or slow down atherosclerosis pro-
gression [95]. Another group of cell surface receptor for
AGEs with opposite function to RAGE, known as AGE-R1,
AGE-R2, or AGE-R3, is instead involved in the regulation
of endocytosis and degradation of AGEs [16, 88]. AGE
detoxification is mediated by other receptors including scav-
enger receptors class A, type II (MSR-AII), and class B, type I
(MSR-BI, CD36) [15, 96].
As previously said, the AGE linked with specific RAGE
has been involved in the activation of critical signaling path-
ways that are responsible for activating the genes linked to
the inflammatory responses [97]. Several AGE accumulation
effects cause stress in endoplasmic reticulum (ER) and induce
apoptosis or activate NF-κB via signaling cascade. ER stress,
for example, is coupled with the activation of MAP kinases
[98]. Genes involved in inflammation are activated by certain
transcription factors, including NF-κB, which has been phos-
phorylated by members of the MAPK family [99–107].
Another mechanism involved in the regulation of protein
synthesis during ER stress concerns the phosphorylation of
the subunit of eukaryotic initiation factor 2 (eIF2) which, in
turn, involves the activation of NF-κB [108] and many cellu-
lar genes that are largely antiapoptotic under ER stress [109].
Apoptosis is a form of programmed cell death or “cellular
suicide.” It is a natural cell death, and it is different from
necrosis, in which cells die due to injury. It plays an impor-
tant role in wound repair by preventing a prolonged inflam-
matory response and excessive scar formation. An abnormal
functioning of the complex apoptotic mechanism causes slow
wound healing and a high state of inflammation. Diabetic
subjects, having high AGE content, are characterized by slow
wound healing and high states of inflammation [110, 111].
It is clear that ER stress activates multiple signal transduc-
tion pathways including eIF2α, MAPK, and NF-κB [99, 111,
112]. These pathways may be partly shared or converge on
common downstream effectors [99, 112]. For example, AGEs









Figure 5: Example of fluorescent non-cross-linked AGEs.
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through the eIF2α, p38 MAPK, and NF-κB pathways in
human chondrocytes [113]. These results explain that carti-
lage degradation in osteoarthritis is associated with latent
ER stress [113]. The accumulation of AGEs in the tissues is
detrimental to the survival of cells that make it up. The pres-
ence of reactive oxygen species induced by AGEs (ROS)
raises carboxylic content of cellular proteins leading to apo-
ptotic events. However, these mechanisms are not always
clarified. Autophagy is significantly related to apoptosis
[114]. Apoptosis and autophagy were related to reactive oxy-
gen species (ROS) production, and in this context, AGEs
induced autophagy [113].
A type of RAGE that involved the pathway of intracellu-
lar oxidative stress is AGE-R1 that has been shown to be
involved in pathways that decrease intracellular oxidative
stress [16]. These receptors are present on the surface of dif-
ferent cell types, including macrophages, vascular smooth
muscle cells, lung cells, and endothelial cells, and activate
scavenging receptor mechanisms [66, 70, 71].
There is also a circulating pool of RAGE, collectively
known as soluble RAGE (sRAGE), whose role remains con-
troversial, and a minor, alternatively spliced isoform of
RAGE known as endogenous secretory RAGE (esRAGE)
[17, 114, 115]. These receptors have been detected in human
plasma. sRAGE is generated by proteolytic cleavage of native
membrane receptors mediated by matrix metalloproteinases
(MMP) [17, 114]. It has been found in plasma and owns a
ligand-binding domain but lacks the transmembrane and
cytoplasmatic domains [17, 115]. In animal studies, admin-
istration of sRAGE prevented and slowed atherosclerosis
[116, 117]. In another study, administration of sRAGE
improved retinal neuronal dysfunction in diabetic mice
[118]. These results [115–118] suggest that sRAGE acts by
trapping, binding, and eliminating circulating AGEs. Another
study, instead, shows that sRAGE represents a marker of
RAGE expression of tissues and disease activity [119]. For this
reason, the exact pathophysiological role of these soluble var-
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Figure 6: Schematic representation of AGEs’ formation and their biological effects.
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by future studies. Frequently, esRAGE and sRAGE are
measured using the enzyme-linked immunosorbent assay
(ELISA). The sRAGE measurements include esRAGE in
order to evaluate the relationship between sRAGE or
esRAGE and inflammation. Human studies have reported a
reduction in serum of sRAGE levels in subjects with inflam-
matory conditions such as atherosclerosis, obesity, rheuma-
toid arthritis, and chronic obstructive pulmonary disease
[120, 121]. In contrast, other studies on diabetic patients have
shown that sRAGE is positively correlated with circulating
inflammatory markers such as TNF-α and MCP [122]. The
opposite results of the sRAGE content between patients with
diabetes and people with other inflammatory conditions are
demonstrated by increased levels of matrix metalloprotein-
ases, since high circulating AGEs, frequently in diabetes, are
linked with increased production and expression of metallo-
proteinases of matrix, thus increasing the proteolytic cleav-
age of sRAGE expressed by the cell surface [123]. Serum
sRAGE levels have been shown to be five times higher in
healthy subjects [124]. Extensive studies on the polymor-
phisms of the RAGE gene will be able to clarify the roles of
sRAGE and esRAGE at the cellular level.
4. Measurements of AGEs
The complex nature of glycation and the widest range of
chemical structures and physical properties lead to difficul-
ties in their measurement. The goal is the detection of all
AGE compounds in a single run. No standardized method
exists, and there is no possibility to compare AGE results in
a meaningful way between different laboratories [18]. In this
context, it is difficult to draw any firm conclusion about the
relative toxicity of these wide classes of AGEs. Table 1 sum-
marizes the different methodologies for the analysis of AGE
with their advantages and disadvantages.
Methods for identification and quantification of AGEs
in biological samples include instrumental methods and
immunochemical methods. The instrumental methods
include the following: (1) spectrofluorimeter [125], (2)
high-performance liquid chromatography coupled with mass
spectrometry (HPLC/MS) [126], (3) gas chromatography
coupled with mass spectrometry (GC-MS) [127], (4) liquid
chromatography coupled with tandem mass spectrometry
(LC-MS/MS) [128], (5) HPLC with fluorescent detection












Functional changes in enzymatic activity and low







































Diabetic complications, cardiovascular disease
atherosclerosis, kidney disease, Rheumatoid arthritis
RAGE
ligand AOPP
Figure 7: Biochemical formation of AGEs, their signaling, and molecular signal transduction that lead to pathological effects.
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chromatography (UHPLC) [130]. Immunochemical methods
are mainly enzyme-linked immunosorbent assay (ELISA)
[131, 132] and Western blotting [133], using antibodies spe-
cific for certain AGE structures.
Estimation of serum, urine, and saliva AGEs might be
measured by spectroscopic and fluorimetric methods. How-
ever, the amount of AGEs quantified by this method provides
only the quantification of fluorescent AGEs. The determina-
tion of fluorescent AGEs is quite simple. Briefly, samples are
diluted (50-fold for serum, 10-fold for saliva, and from 10- to
200-fold for urine) with phosphate-buffered saline (PBS) at
pH 7.4 and the amount of AGEs is measured at λex = 370
nm and λem = 440 [10]. The specific fluorescence of AGEs
is expressed in arbitrary units.
A simple, noninvasive, and rapid in vivo technique allows
the detection of AGEs in the skin, by use of autofluorescence
spectroscopy [25].
This method employs an ultraviolet A radiation of
370nm (at low intensity) interacting with AGEs in the skin.
The light emission is measured at 440nm from the skin using
a spectrometer portable.
Importantly, many studies have shown the validity of
AGE reader in the skin and its significant correlation to total
AGE content measured by high-performance liquid chroma-
tography (HPLC), which however requires invasive collec-
tion of skin samples [25, 60, 134]. In particular, authors
have shown that skin AGE levels of different patient groups
and healthy controls, measured by AGE reader, are signifi-
cantly correlated to levels of both fluorescent (e.g., pentosi-
dine) and nonfluorescent AGEs (e.g., carboxymethyl-lysine
and carboxyethyl-lysine) assessed in skin biopsies [25, 60,
135], even if the major contribution in fluorescence comes
from fluorescent AGEs. Moreover, skin AF has been shown
to be highly a significant predictor of long-term diabetic
complications (5-10 years) compared to short-term glycemic
memory reflected from haemoglobin A1c (HbA1c) (3-6
months) [136, 137] because skin AF represents the “long-
term memory” of cumulative metabolic stress compared to
HbA1c or other conventional risk factors (e.g., smoking
and blood pressure).
It has been observed that skin AF is also correlated with
the progression of complications of renal failure and cardio-
vascular ones, being a marker to produce advanced glycation
end products [60, 127].
Different studies describe the influence of different
absorptions of excitation or emission of light by darker skin
Table 1: Methods for measuring AGEs in the human samples. The advantages and disadvantages of various assessment methods.
Methods Marker Compartment Advantages Disadvantages
Fluorimetric method:
λex = 370 nm,







(i) No detection of nonfluorescent
AGEs
(ii) Interference of non-AGE fluorophores
(iii) Results expressed in arbitrary units
Autofluorescence
spectroscopy:
λex = 370 nm,






(i) Noninvasive, simple, rapid
method
(ii) Applicable to clinical or
epidemiological studies
(iii) Significant correlation with
AGEs measured by HPLC
(i) Major contribution in fluorescence
comes from fluorescent AGEs
(ii) AGE level is lower in dark skin than





(i) A bit invasive
(ii) Suitable for AGE monitoring
(i) More costly in time and efforts





CML, CEL, etc. Urine
(i) Sophisticated technique
(ii) High sensitivity































(i) A bit invasive
(ii) Simple, fast, inexpensive
(iii) No needs for sophisticated
laboratory equipment
(i) Lack of enough antibody specificity
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colours which result in lower values than in subjects with
fair skin colours [138]. Recently, a new algorithm based
on comparison on these results has been validated to assess
skin AGEs independently of skin colour [127]. Spectro-
scopic autofluorescence (SAF) is considered a noninvasive,
rapid, accurate, and safe assessment of AGEs in the skin
[139] and is associated with oxidative stress, in which this
latter induces complications of diabetes, including stroke,
neuropathy, retinopathy, and nephropathy [140]. This tech-
nique is easy to use and is applicable to epidemiological
studies with healthy subjects and those having risk of devel-
oping the disease, even considering any limiting factors,
explained later.
Although SAF plays an important role in characterizing
and predicting an individual’s metabolic health, autofluores-
cence measurement methods have several limitations that
must be improved to increase their relevance in the clinical
setting. SAF measurement may not represent only the AGEs
in the skin content. The presence of endogenous fluorescent
signals from cutaneous fluorophores (i.e., nicotinamide ade-
nine dinucleotide) has the same excitation and emission
ranges (respectively, 350–410 and 420–600nm) and may
interfere with the correct total fluorescence measurement
[135]. SAF method is currently used for research purposes,
and future use in the daily clinic would require further stud-
ies. Its advantages constitute one positive perspective for
future patient monitoring in order to limit the incidence of
diabetes complications and various chronic diseases in which
oxidative stress and inflammation are involved. So far, SAF
measures contain various technical aspects of problems that
are still being improved. Therefore, further research studies
will aim to improve and consolidate this technique. A
research group has developed a new imaging system with
transmission geometry for SAF measurement in order to
improve possible and future diagnostic performance [131].
However, these measurements were carried out on a limited
number of Korean subjects [131]. Soon, it is hoped that
SAF will be available as a noninvasive technique, relatively
cheap and easy to use in ambulatory practice.
Sophisticated and expensive laboratory techniques, such
as mass spectroscopy and gas and/or liquid chromatography,
provide exceptional sensitivity and specificity for detection
and quantification of specific AGEs, but there is a need for
highly qualified personnel and high costs, and for these rea-
sons, these techniques have difficulties in widespread use.
For example, liquid chromatography coupled with mass
spectrometry gives higher sensitivity than the fluorescence
detection method (HPLC with fluorescence detector) [127].
Liquid chromatography coupled with tandem mass spec-
trometry (LC-MS/MS) has been used for the analysis of non-
volatile compounds [121]. One major advantage is that
usually no derivatization step is required. Besides, the use of
a tandem MS system offers improved sensitivity.
Gas chromatography coupled with mass spectrometry
(GC-MS) has been widely used for the analysis of CML
and CEL in urine and protein hydrolysates [134] or used
to quantify the amount of CML in different food samples
[119]. A new method based on ultra-high-pressure liquid
chromatography (UHPLC) is involved in the use of smaller
particles (1.7μm) which allow faster analysis and better
resolution.
In general, measurements of N-carboxymethyl-lysine,
pentosidine, and methylglyoxal (MG) which are used as
AGE biomarkers have mainly been analyzed by LC-
MS/MS and competitive ELISA [124, 125]. This method
uses monoclonal antibody specific for AGE, developed to
measure of AGEs in different human tissues, biological
samples, and foods. This procedure is relatively simple, fast,
and inexpensive, and there is no need for sophisticated labo-
ratory equipment. However, the disadvantages are as follows:
(1) the lack of enough antibody specificity, depending on the
commercial kit used, and (2) interference with glycation-free
adducts [136, 137]. In this context, the assessment of AGE by
immunoassay does not measure AGE levels in absolute
concentrations but rather in arbitrary units with or with-
out normalization to a reference AGE glycated protein
standard [22, 125]. However, some problems result from
the use of biological samples rather than food samples.
In recent years, new promising methodologies for high-
throughput generation of monoclonal antibodies mapped
with epitopes against AGE have been applied and validated.
For example, recent studies have allowed the generation of
new monoclonal antibodies destined for carboxymethyl-
lysine [26, 27]. Monoclonal antibodies have the potential to
detect and quantify single glycated epitopes, but the effective
and specific ones currently available are limited. Other avail-
able monoclonal antibodies have not described epitopes and
do not show specific bonds [137]. Therefore, there is a great
need for monoclonal antibodies with a well-defined binding
pattern, to bridge the specificity gap and create a basis for
better analytical capacity.
Immunological methods could potentially offer several
advantages in identifying these compounds, such as the rapid
achievement of results, greater detection sensitivity, and sim-
pler application [135, 139, 140]. However, improvements in
cultivation techniques and in the construction of specific
monoclonal epitopes represent important goals to be achieved.
Currently, no gold standard method is available for the
detection and quantification of AGEs. A possible explana-
tion for this is that there is no internationally recognized
standard unit of measurement for expressing AGE levels,
unlike other measurable molecules. These molecules are
characterized by complex structural and molecular heteroge-
neity. As a result, it is extremely difficult to compare the
results between different laboratories.
ELISA have been used extensively for the detection of
AGEs in serum or other biological samples or food matrices.
This technique exploits the use of monoclonal or polyclonal
antibodies [139, 140]. It has yet some limitations represented
by (1) lack of antibody specificity, (2) high background
responses due to the significant content of protein glycation
adduct [141], and (3) interference with glycation-free adducts
[142] due to pretreatment techniques, such as heating and
alkaline treatment [22, 143]. Major improvements have been
recently made, and the use of ELISA has made important con-
tributions to be easily used in the measurement of CML in
plasma and urine [144] and in various foods [145]. A signifi-
cant relationship between CML determined by ELISA and
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HPLC-ESI-ITMS/MS analysis was demonstrated recently.
This involves the implementation of ELISA in food CML/AGE
screening [145].
Serum AGEs, RAGEs, and sRAGEs may be measured by
Western blotting. Samples are initially separated by SDS-
PAGE (10% gel), and gel is electrotransferred to polyvinyli-
dene difluoride membrane. Nonspecific binding sites of pro-
teins are blocked with TBST (Tris-buffered saline containing
Tween 20) with 10% powdered skimmed milk. The blocked
membrane is incubated at room temperature for 1 hour with
rabbit anti-human AGE polyclonal antibody, goat anti-rabbit
IgG, or polyclonal goat Ab against human RAGE. Bands are
visualized and analyzed [36] by an enhanced chemilumines-
cence advanced detection system and then exposed to X-ray
film (e.g., Kodak).
Western blotting (WB) is an analytical method for iden-
tification and quantification of a specific protein such as
AGE-modified ones in biological samples. Fluorescent-
labeled primary enzymes or antibodies with ability to bind
to the specific antigen are generally employed in Western
blotting. Although WB is accepted as a routine protein anal-
ysis technique, it has benefits and limitations [145, 146]. WB
has a high sensitivity. Due to its ability to detect up to 0.1
nanograms of protein in a sample, the technique could prove
to be an effective early diagnostic tool. In addition, the WB
technique owes its specificity to two major contributing fac-
tors. The gel electrophoresis step order proteins of different
size, charge, and conformation, representing fundamental
clues on the size of the protein or polypeptide of interest.
Subsequently, the specificity of the antibody-antigen interac-
tion acts as a second major factor for a specific detection. All
these aspects allow to selectively detect a target protein even
in a mixture consisting of thousands of different proteins.
Despite its high sensitivity and specificity, WB could still pro-
duce incorrect results [145, 146]. For example, false positives
could occur when an antibody reacts with an unintended
protein. A false negative, on the other hand, could occur if
large proteins do not have enough time to properly transfer
to the membrane. For this reason, distorted, faded, or even
multiple bands could appear providing wrong misunder-
stood results. WB requires high costs due to the use of anti-
bodies, expert analysts, and laboratory equipment. The
technique requires precision in each phase, and a trivial error
in one step could compromise the whole process. Finally, the
equipment needed for detection and imaging (chemilumi-
nescent, fluorescent, radioactive, or laser detection systems)
can be too expensive [145, 146]. Western blotting has the
benefit of allowing simultaneous detection of several targets,
whereas ELISA can detect only one product. It is also possible
to determine the size of the target to be analyzed, and there-
fore, it is also possible to (semi-) quantify the AGE or RAGE
of interest by running a gel with the sample containing the
target protein of interest and in parallel with a quantity of
standard. Compared to ELISA, Western blotting is more
time-consuming and has a higher demand in terms of expe-
rience and required experimental conditions (i.e., protein
isolation, buffers, type of separation, and gel concentration).
In conclusion, the most suitable technique for specify-
ing the application depends on several available factors
such as trained personnel, available laboratory, financial
resources, and object of the study (AGE concentration, num-
ber of samples, type of samples, etc.). However, the chosen
methodology is important to provide reliable data, especially
if these data are a reliable tool to monitor the healthy sub-
jects, the effects of therapeutics, and the progression of a
pathological status.
5. Epigenetic Effects of AGEs
AGEs have negative effects on cells and tissues, and the
enhanced accumulation in hyperglycemic patients has
caused atheroarteriosclerosis and type II diabetes. Evidence
has shown that epigenetic mechanisms are induced by AGEs
due to the RAGE. These processes can be reduced by ROS
scavengers such as oligo- and polysaccharides and L-carno-
sine, catalase, and rhamnose-rich molecules [147]. Cytotox-
icity associated with hyperglycemia can occur not only in
the skin in other tissues due to the cross-linking of collagen
with Maillard reaction products with induced cytotoxic
effects on cells. Epigenetic processes are those mechanisms
that induce variation in gene expression and phenotype due
to genetic modifications that do not deal with alterations of
the DNA sequence. Epigenetic changes can be divided into
their short- or long-term effects. The short-term effect is a
rapid response to an environmental factor that is typically
not transmitted in the filial generation. The long-term effects
induce a persistent modification that remains as “memory,”
and it is heritable, typically in response to a long-term and
intensive environmental stimulus [148]. It is worthy to notice
that also a transient modification to a short environmental
change may provoke a permanent epigenetic effect [138].
The epigenetic effects of AGEs have been investigated in
relation to the occurrence of diabetes and other chronic dis-
eases. Together with tumor necrosis factor, AGEs induced
MMP-9 promotor demethylation although this complex
mechanism is still unclear. DNAmethylation of MMP-9 pro-
moter is mediated by the involvement of GADD45a, growth
arrest, and DNA damage protein 45 that is a member of a
small family of stress-responsive genes [144]. GADD45a
was linked to diabetes and diabetic cardiomyopathy, and it
was shown to interact with proteins involved in DNA meth-
ylation. The real role played by GADD45a in MMP-9 pro-
moter demethylation has been partially recently elucidated.
GADD45a expression was induced in the skin of patients
showing diabetic foot ulcers. In addition, this gene was
upregulated in diabetic rats, and in humans, keratinocyte
(HaCaT) cells were treated with AGEs [147]. A partial pos-
itive correlation between the expression of GADD45a and
MMP-9 was observed. The knockdown of GADD45a sup-
ported the upregulation of MMP-9 transcription through
the downregulation of demethylation in the MMP-9 pro-
moter [148].
Recent studies have highlighted the role played by epige-
netic mechanisms in the well-studied phenomenon of meta-
bolic memory of diabetes [149]. The pathological effects of
hyperglycemia are due to four basic mechanisms: PKC acti-
vation, enhanced production of AGEs, enhanced glucose flux
due to polyol pathway, and upregulation of hexosamine
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pathway activity [150, 151]. Hyperglycemic status has been
associated with the activation of histone modifications that
provoke the enhanced expression of inflammatory genes
[152]. Interestingly it was observed that these chromatin
remodeling changes, as well as histone modifications in pro-
moters, were maintained even if glucose levels become nor-
mal implying that epigenetic changes are closely associated
with metabolic memory. A work conducted in human podo-
cytes has shown that AGEs downregulated NAD-dependent
deacetylase sirtuin 1 (SIRT1), provoking enhancement of
acetylation of key transcription factors such as STAT3, NF-
kappaB-p65 (NF-κB (p65)), and FOXO4 [153]. The acetyla-
tion of STAT3 upregulated proinflammatory genes causing
podocyte apoptosis and consequently kidney disease. Further
studies are needed to investigate genes targeted by epigenetic
mechanisms of dietary AGEs. Epigenetic mechanisms are the
base of the regulation of hyperglycemic memory that is the
phenomenon that drives a hyperglycemic state in the absence
of causing factors but associated with a previous hyperglyce-
mic state (Figure 6). This pathological status has been associ-
ated with oxidative stresses and occurrence of AGE as well as
the induction of pathways of mitogen-activated protein
kinase [154, 155]. The induction of ROS in mitochondrial
structures has been associated with the induction of path-
ways of hyperglycemic disease such as the upregulation of
polyol pathways, induction of protein kinase C signaling,
and enhanced production of AGEs [156]. The epigenetic
mechanism has been linked to the expression of NF-κB-p65
[157] and the occurrence of permanent epigenetic marks
such as enhanced levels of H3K4 and reduced H3K9 methyl-
ations at the promoter of p65 gene [158]. The methylation
patterns are caused by the activity of enzymes with opposite
effects such as histone methyltransferase SET7 and histone
demethylase LSD1. Silencing of SET7 has been associated
with metabolic memory through the action of DNMT1
methylation that directs it to its degradation via proteasome
[159]. On the contrary, LSD1 seems to avoid DNMT1 degra-
dation eliminating the methylation mark. Indeed, metabolic
memory should be caused by the competition between the
epigenetic action of SET7 and LSD for methylation changes
at DNMT1. A recent cohort study has shown the link
between specific histone modifications and glycemic mem-
ory such as enhanced acetylation of H3K9 at promoters of
genes involved in interferon regulatory factors, inflamma-
tion, apoptosis, and oxidative stresses occurring in mono-
cytes. Also, DNA methylation changes have been linked
with diabetic vascular complications such as hypermethyla-
tion in the UNC13B promoter present in patients affected
by diabetic nephropathy. DNA methylation has been linked
to glycemic memory and diabetic retinopathy [160]. Indeed,
the promoter of POLG1 was shown to be hypermethylated
and associated to glycemic memory [161]. Inflammation is
a typical pathological status due to a response to pathogen
attacks and tissue offense. This process is modulated by dif-
ferent environmental factors such as enhanced expression of
Toll-like receptors (TLRs) and upregulation of epigenetic
modifications of RAGE [162]. Viral meningoencephalitis
induced an inflammatory status that is associated with the
induction of methyl-CpG protein 2 (MeCP2), an epigenetic
factor essential for methylation of DNA. In the early stage
of this disease, Purkinje cells have receptors recognized by
pathogens that induce self-destructive mechanisms in these
neurons. In later stages of viral meningoencephalitis, RAGE
protein was observed in the adult brain and aging patients
implying that the inflammatory process might be modulated
by numerous posttranslationally modified proteins moving
to the brain after binding with activated RAGE [163]. The
effect of inflammation is the elimination of necrotic cells
and the induction of repair pathways. However, the activa-
tion of proinflammatory proteins may provoke chronic dis-
eases. Endogenous proteins may deregulate inflammation
binding to RAGE and move to inflamed tissues where they
regulate defense immune responses. Inflammation may be
modulated by epigenetic modifications such as the activity
of DNA methyltransferases such as methyl-CpG binding
proteins (MeCP2), histone-modifying enzymes, and chro-
matin remodeling proteins and protein complexes. The most
associated DNA methylation change is occurring at cytosine
that affects gene expression and genomic imprinting [164]
linked to cancer and mental retardation disorders.
Diabetic retinopathy (DR) is a pathological status that
is caused by an enhanced incidence of diabetes mellitus.
Therapeutic treatments are scarce [165]. Studies have shown
that DR may be due to persistent epigenetic modifications
because the improvement of diabetes mellitus does not imply
beneficial effects on DR even in the long term. This is corrob-
orated by other evidence that has linked epigenetic modifica-
tions to complications of diabetes [166].
Thioredoxin-interacting protein (TXNIP) has been
linked to the promotion of diabetes and its vascular patho-
logical effects. The binding of S100B and the RAGE promote
the expression of TXNIP and inflammatory genes such as
Cox2, VEGF-A, and ICAM-1. TXNIP-induced inflammation
has been linked to nine histone modifications on H3 lysine.
The p38 MAPK-NF-κB signaling pathway has been involved
in inflammation driven by TXNIP. Induction of TXNIP in
endothelial cells promotes inflammation, silences H3K9 tri-
methylation, and enhances H3K9 acetylation at the proximal
promoter of Cox2 [167].
In conclusion, in this review, we have briefly described
the current methodologies for AGE’s detection highlighting
advantages and disadvantages in addition to essential princi-
ples in AGE’s biochemistry, signaling, and epigenetic effects.
Efforts in AGE’s identification using these techniques to dis-
cover reliable aging AGR-related markers are ongoing.
These methodologies can be divided into two main catego-
ries: chemical and molecular biology. Aspartic acid racemi-
zation is probably the most accurate technique available
[168], although epigenetic methods are also getting more
popularity. The development of portable instruments for
AGE’s detection for an easy and rapid detection in blood
or saliva will be highly desirable and might be soon intro-
duced in the market. These systems might be based on pro-
tein, mRNA, or noncoding RNA (miRNA, lncRNA, etc.)
detection once reliable markers will be discovered. These sys-
tems should be based on the analysis of a pool of biomarkers
since one specific marker linked with AGE’s increase will be
hardly discovered.
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